S
Scilex Holding Company (SCLX)
NCM – Real Time Price. Currency in USD
6.81
-0.09 (-1.30%)
At close: May 12, 2026, 4:00 PM EDT
7.06
+0.25 (3.67%)
After-hours: May 12, 2026, 5:14 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.81
-0.09 (-1.30%)
At close: May 12, 2026, 4:00 PM EDT
7.06
+0.25 (3.67%)
After-hours: May 12, 2026, 5:14 PM EDT
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California.
| Name | Position |
|---|---|
| Dr. Dmitri V. Lissin M.D. | Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer |
| Dr. Henry H. Ji Ph.D. | CEO, President & Executive Chairman |
| Dr. Suketu D. Desai Ph.D. | Interim Chief Technical Officer & Senior VP |
| Mr. Stephen Ma | Senior VP, CFO, COO, Corporate Secretary & Director |
| Mr. Suresh K. Khemani | Senior VP, Chief Commercial Officer & GM of Scilex Pharma |
| Ms. Gigi DeGuzman | VP & Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | DEFA14A | d298016ddefa14a.htm |
| 2026-04-30 | DEF 14A | d146109ddef14a.htm |
| 2026-04-28 | 8-K | sclx-20260426.htm |
| 2026-04-16 | S-3 | d897596ds3.htm |
| 2026-04-10 | 10-K | sclx-20251231.htm |
| 2026-04-01 | NT 10-K | scilex_nt_10k_2025.htm |
| 2026-03-13 | 8-K | sclx-20260313.htm |
| 2026-02-20 | 8-K | sclx-20260219.htm |
| 2026-02-13 | DRS | filename1.htm |
| 2026-02-09 | S-8 | d28614ds8.htm |